IL31 and Alzheimer disease: Nemolizumab, which targets IL-31 receptor α, has demonstrated promising efficacy in alleviating itching and improving symptoms in AD patients aged 12 years and older16, but the efficacy of this biologic was only temporary, suggesting that IL-31 has no upstream role in the pathogenesis of AD.147